Drug Trial Radar · NCT07756957
Safety of the Acne mRNA Vaccine in Adolescents 12 to 17 Years of Age With Moderate to Severe Acne
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
410
Planned (sponsor's estimate)
Start
Oct 14, 2026
Primary completion
Jul 19, 2028
Study completion Feb 19, 2029
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Aug 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety profile of intramuscular injections of the Acne mRNA vaccine at 3 dose levels compared with placebo in 12 to 17 years old participants with moderate to severe acne. An early safety data review (ESDR) will be conducted after each subcohort has completed an injection round; enrollment of the next higher dose level subcohort or progression of a subcohort to the subsequent injection round will only proceed if no safety concerns are identified. This sequential process will allow a cautious approach to vaccine injection in the adolescent population. Study details are as follows: * Before being enrolled in the study, participants complete a 4-week (ie, 1-month) screening period during which they will be called over the telephone approximately in the middle of the screening period to check they are not using prohibited medications and to remind them about the facial hygiene requirements. * Once the screening period has been completed, the study duration will be up to 13 months for each participant * Participants will be invited to a long-term extension study through a separate protocol.
Conditions
- Acne
Interventions
Acne mRNA (messenger ribonucleic acid) vaccineBiological
IM injection
PlaceboBiological
IM injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Unsolicited systemic AEs (Adverse Events)Time frame: 30 minutes after each injection
- Solicited injection site and systemic adverse reactionsTime frame: 8 days, including the day of each injection
- Unsolicited AEsTime frame: 28 days, including the day of each injection
- SAEs (Serious Adverse Events), MAAEs (Medically Attended Adverse Event), AESIs (Adverse Event of Special Interest) and AEs (Adverse Events) leading to study discontinuationTime frame: Up to 2 months after last injection
- Out-of-range biological test results (including shift from baseline values)Time frame: Within 8 days after each injection, including the day of injection
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Investigational Site Number : 1240001
Edmonton, Alberta, Canada · Recruiting
Investigational Site Number : 1240013
Edmonton, Alberta, Canada · Recruiting
Investigational Site Number : 1240009
Vancouver, British Columbia, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.